2,2-dimethyl-hept-6-enoic acid ethyl ester | 143958-75-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,2-dimethyl-hept-6-enoic acid ethyl ester
• 英文别名: ethyl 2,2-dimethylhept-6-enoate
• CAS: 143958-75-2
• 化学式: C₁₁H₂₀O₂
• 分子量: 184.279
• InChiKey: QZENFFXGFBABAU-UHFFFAOYSA-N

物化性质

• 沸点：
  220.4±19.0 °C(Predicted)
• 密度：
  0.882±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-hept-6-enoic acid ethyl ester 在 盐酸 、 sodium hydroxide 、 磺酰氯 、 次氯酸叔丁酯 、 叠氮磷酸二苯酯 、 sodium hydride 、 溶剂黄146 、 三乙胺 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 18.0h， 生成 2-methyl-hepta-1,6-diene
  参考文献：
  名称：

  Attempts to trap radicals formed in solution by a magnesium surface

  摘要：

  The synthesis of 2,2-azo-2-methyl-6-heptene (1) is described. Photolytic decomposition of 1 in ether gave rise to the 1,1-dimethyl-5-hexenyl radical clock (2) which yielded 1,1,2-trimethylcyclopentane (3), 6-methyl-1-heptene (4), and 2-methyl-1,6-heptadiene (5) in the ratio of 1:0.72:0.56, respectively. The ratio did not change appreciably when a well-stirred mixture of 1 and 5 equiv of magnesium powder was photolyzed. Moreover, the solution gave a negative test (2,2'-biquinoline) for the presence of Grignard reagent. Thus, it has been experimentally demonstrated that the radicals formed in solution do not react with a magnesium surface to form Grignard reagents.

  DOI：

  10.1021/jo00049a026
• 作为产物：
  描述：

  5-碘-1-戊烯 、 异丁酸乙酯 在 正丁基锂 、 N-环己基异丙基胺 作用下， 生成 2,2-dimethyl-hept-6-enoic acid ethyl ester
  参考文献：
  名称：

  Attempts to trap radicals formed in solution by a magnesium surface

  摘要：

  The synthesis of 2,2-azo-2-methyl-6-heptene (1) is described. Photolytic decomposition of 1 in ether gave rise to the 1,1-dimethyl-5-hexenyl radical clock (2) which yielded 1,1,2-trimethylcyclopentane (3), 6-methyl-1-heptene (4), and 2-methyl-1,6-heptadiene (5) in the ratio of 1:0.72:0.56, respectively. The ratio did not change appreciably when a well-stirred mixture of 1 and 5 equiv of magnesium powder was photolyzed. Moreover, the solution gave a negative test (2,2'-biquinoline) for the presence of Grignard reagent. Thus, it has been experimentally demonstrated that the radicals formed in solution do not react with a magnesium surface to form Grignard reagents.

  DOI：

  10.1021/jo00049a026

文献信息

• FATTY ACID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREFOR
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20190039989A1

  公开（公告）日：2019-02-07

  The present invention relates to a class of fatty acid compounds, a preparation method thereof and use thereof. The fatty acid compounds have the structure of the formula I, which has the ability to activate APMK and inhibit the glucose output in mouse primary hepatocytes. The fatty acid compounds can be used in preparing a medicament for the treatment of obesity or diabetes.

  本发明涉及一类脂肪酸化合物，其制备方法和用途。这些脂肪酸化合物具有式I的结构，具有激活APMK并抑制小鼠原代肝细胞中葡萄糖输出的能力。这些脂肪酸化合物可用于制备治疗肥胖或糖尿病的药物。
• Primary Anion–π Catalysis of Epoxide‐Opening Ether Cyclization into Rings of Different Sizes: Access to New Reactivity
  作者：Miguel Paraja、Stefan Matile

  DOI：10.1002/anie.202000579

  日期：2020.4.6

  a promise anion-π catalysis has been reluctant to live up to. Herein, we report non-trivial reactions that work with anion-π catalysis, but not with Brønsted acids, under comparable conditions. Namely, we show that the anion-π templated autocatalysis and epoxide opening with alcoholate-π interactions can provide access to unconventional ring chemistry. For smaller rings, anion-π catalysis affords anti-Baldwin

  阴离子-π催化的概念集中在芳族π表面上阴离子过渡态的稳定化。最近，我们证明了在芳香族π表面上环氧化物开放醚环化的发生。尽管反应是通过非常规机制进行的，但所得产物与常规布朗斯台德酸催化的产物相同，并且符合鲍德温选择性规则。然而，不同的机制最终应该导致新产品的出现，阴离子-π催化一直不愿实现。在本文中，我们报告了在可比条件下适用于阴离子-π催化而不适用于布朗斯台德酸的非平凡反应。即，我们证明了阴离子-π模板化的自催化和具有醇盐-π相互作用的环氧化物开环可以提供非常规环化学的途径。对于较小的环，阴离子-π催化作用可提供抗鲍德温氧杂环戊烷，2-氧杂双环[3.3.0]辛烷，以及通过甲基迁移使鲍德温氧杂环丁烷膨胀。对于较大的环，阴离子-π模板自催化被认为减轻了折叠的熵损失，从而使不利的反鲍德温环化成为氧杂环丁烷和氧杂环丁烷。
• Rational Design, Synthesis and Biological Evaluation of Modular Fluorogenic Substrates with High Affinity and Selectivity for PTP1B
  作者：Silvano Sanchini、Francesca Perruccio、Grazia Piizzi

  DOI：10.1002/cbic.201400033

  日期：2014.5.5

  released through an enzyme‐initiated 1,6‐elimination reaction. Optimisation of the stereoelectronic properties and of the binding interactions at the enzyme active site led to substrates with high affinity and promising selectivity.

  智能探针：氨基香豆素潜在的发色团通过酶引发的1,6消除反应释放。立体电子性质和在酶活性位点的结合相互作用的优化导致底物具有高亲和力和有希望的选择性。
• 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
  申请人：Barnes David

  公开号：US20100035942A1

  公开（公告）日：2010-02-11

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  式（I）的化合物是蛋白酪氨酸磷酸酶（PTPase）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，例如SH2结构域。因此，式（I）的化合物可用于预防和/或治疗与肥胖相关的胰岛素抵抗、葡萄糖不耐受、糖尿病、高血压和大、小血管缺血性疾病，伴随2型糖尿病的疾病，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常以及其他表现为胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。
• 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors
  申请人：Novartis AG

  公开号：US08252820B2

  公开（公告）日：2012-08-28

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式为的化合物是蛋白酪氨酸磷酸酶（PTPase）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖耐量不良、糖尿病、高血压和大、小血管缺血性疾病有关的胰岛素抵抗症状。这些疾病包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常和其他胰岛素抵抗症状。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。